Introduction
Dendritic cells (DCs) are bone marrow-derived cells absolutely required for the proper generation of adaptive immunity and tolerance. Upon antigen recognition, immature DCs localized in the peripheral tissue acquire the ability to act as antigen presenting cells and home to T-cell zones of lymphoid organs where they stimulate antigen-specific naïve T cells (Steinman and Banchereau 2007) . Acquisition of the DC immuno-competent phenotype is achieved by a finely regulated genetic program that modulates the expression of many genes required to accomplish DC immune functions effectively. Among them, induction of expression of the chemotactic receptor CCR7 provides DCs the major guidance clue to traffic towards lymphoid organs (Forster et al. 1999) . Chemokines CCL21 and CCL19 induce CCR7-mediated G protein activation, which indeed triggers the multiple signaling modules required for the mobilization of DCs to lymphoid tissues (Randolph et al. 2008) . Besides CCR7, other accessory cell surface proteins, such as CD38, and the PGE2 receptors EP2 and EP4 are also known to influence DC migration to secondary lymphoid organs (Randolph et al. 2005) .
Polysialic acid 2,8-linked N-acetylneuraminic acid (PSA) is a large linear homopolymer post-translationally added to a small number of proteins (Muhlenhoff et al. 1998 ). On the major carrier protein NCAM, PSA plays a critical role in the development of the vertebrate nervous system (Rutishauser 2008) , where it controls neuronal and olygodendrocyte migration and alters cell-cell and cell-extracellular matrix interactions. PSA also regulates migration of T-cell progenitors from the bone marrow to the thymus (Drake et al. 2009 ). Two polysialyltransferases (ST8SiaII and IV) are known to be responsible for the polysialylation of NCAM and other acceptor molecules (Angata and Fukuda 2003) . The expression of the polysialyltransferase ST8SiaIV is induced in mature DCs, where it is likely involved in synthesizing PSA on O-linked glycans of the 130-kDa membrane glycoprotein neuropilin-2 (NRP2), whose expression is also upregulated during DC maturation (Curreli et al. 2007 ). Polysialylation in DCs has been demonstrated to contribute to T-cell allostimulation (Curreli et al. 2007 ). More recently, it has been reported that PSA controls CCL21-directed migration of mature DCs (Bax et al. 2009 ), although its role in CCL19-driven chemotaxis has not been explored yet. NRP2, through binding to its structurally unrelated ligands, semaphorins B, C and F, and some members of the VEGF family, has been implicated in cell motility, including neuronal growth cone collapse and endothelial and tumor cell migration (Geretti et al. 2008; Pellet-Many et al. 2008) . The expression of PSA and NRP2 in mature DCs and their involvement in cell migration prompted us to investigate their roles in CCR7-mediated DC chemotaxis.
In this work, we show that PSA has no enhancing effect on human DC migration towards CCL19. We also report that pre-vention of DC polysialylation decreases CCL21-triggered activation of the CCR7-chemotaxis-associated JNK and Akt signaling pathways. Moreover, our results indicate that the PSA enhancing effect on CCL21-driven chemotaxis of DCs depends on the highly basic C-terminal region of the chemokine and is mediated by the PSA acceptor glycoprotein NRP2.
Results
PSA selectively enhances mature DC chemotaxis towards CCL21 but not towards CCL19 PSA was recently shown to enhance migration in response to CCL21 of lipopolysaccharide (LPS)-induced mature DCs (Bax et al. 2009 ). We wondered if this effect was also shared by CCL19, the other CCR7 ligand. For this purpose, LPS-matured human DCs were treated with the EndoN enzyme to remove surface PSA, and their ability to migrate towards CCL21 or CCL19 was compared with that displayed by untreated DCs. EndoN treatment resulted in complete PSA removal, as assayed by western blotting ( Figure 1A , upper panel, compare lines 1 and 2) and flow cytometry ( Figure 1A , lower panel). PSA content recovery was measured at distinct times after EndoN treatment to assure that no significant PSA re-expression occurs during the chemotaxis assays. In this regard, less than 20% of PSA content was recovered 8 h after DC-EndoN treatment, a time that exceeded the 2-h period of time required to complete the chemotaxis experiments ( Figure 1A , upper panel). Chemotaxis assays in response to each chemokine revealed that EndoN-treated DCs showed significant reduced migration towards CCL21 (average percentage of migration of EndoN-treated DCs with respect to untreated DCs was 52%, P = 0.000045, N = 19), but not towards CCL19 (average percentage of migration of EndoN-treated DCs with respect to untreated DCs was 92%, P = 0.37, N = 15) ( Figure 1B) . Interestingly, reduction of migration towards CCL21 after PSA removal was even stronger when suboptimal doses of CCL21 were used (average percentage of migration of EndoN-treated DCs with respect to untreated DCs was 27%, P = 0.009, N = 4) ( Figure 1C ). Addition of CCL21 to both the upper and the lower chambers of the migration transwells revealed no differences in the number of DCs that migrated to the lower chambers when EndoNtreated and non-treated DCs were compared, which indicated that the effects of PSA were exerted on CCL21-dependent chemotaxis and not on migratory speed (unpublished data). Moreover, EndoN treatment of DCs did not modify CCR7 expression levels as determined by western blotting ( Figure 1D ) and flow cytometry ( Figure 1E ). The absence of differences in the CCR7 molecular size between EndoNtreated and untreated DCs ( Figure 1D ) strongly suggests that CCR7 is not polysialylated. The above data indicate that cell surface PSA does not affect migration of mature DCs towards CCL19, implying that PSA selectively contributes to CCL21-directed DC migration.
Removal of PSA in DCs decreases CCL21-induced CCR7-mediated signaling CCL21 triggers CCR7-mediated G protein activation that results in the activation of multiple signaling pathways (Randolph et al. 2008 ). Of them, JNK activation has been associated with DC migration in response to chemokines (Iijima et al. 2005; Riol-Blanco et al. 2005) and Akt activation with promotion of DC migration (Del Prete et al. 2004 ) and survival (Sanchez-Sanchez et al. 2004) . To examine the signaling pathways underlying the PSA-mediated enhancement of CCL21-directed chemotaxis, CCL21-induced JNK and Akt phosphorylation levels were compared between EndoN-treated and untreated mature DCs. While more pronounced transient JNK and Akt phosphorylations were observed in untreated DCs than in EndoN-treated DCs upon stimulation with CCL21 (Figure 2A ), no differences were observed upon stimulation with CCL19 ( Figure 2B ). These results indicate that PSA enhances CCL21-driven signaling likely through CCR7 and are consistent with the increased migration towards CCL21 observed in PSA-bearing DCs with respect to DCs devoid of PSA.
PSA enhancement of CCL21-driven chemotaxis relies on the highly basic C-terminal amino acid region of the chemokine As shown before and unlike the case of CCL21, no PSAenhancement effect on CCL19-directed chemotaxis was observed ( Figure 1B) . A striking structural difference between CCL21 and CCL19 is the presence of a highly basic C-terminal 32-amino-acid-long region in CCL21, which is absent in CCL19 ( Figure 3A ). This region has been suggested to interact with glycosaminoglycans to mediate the sequestration of CCL21 in endothelial cells to facilitate the formation and maintenance of the CCL21 gradient (Hirose et al. 2002) . In this regard, highly negatively charged PSA present on polysialylated proteins in DCs is likely to interact with the basic C-terminal region of CCL21. Such an interaction would resemble the interaction of CCL21 with negatively charged glycosaminoglycans (Hirose et al. 2002) and sulfated chains coupled to PSGL-1 on T cells (Veerman et al. 2007 ). Furthermore, the cationic neurotrophic factors brain-derived neurotrophic factor, nerve growth factor, neurotrophin-3 and neurotrophin-4 have been demonstrated to directly interact with PSA (Kanato et al. 2008) . Interestingly, PSA coupled to biotinylated polyacrylamide has been recently shown to interact with CCL21 in vitro (Bax et al. 2009 ). The above reasoning prompted us to test whether the basic C-terminal region of CCL21 contributes to the PSA effect on CCL21-directed chemotaxis. To that end, a CCL21 mutant lacking the last 32 C-terminal amino acid residues (designated as St CCL21-stop) was generated and expressed in the supernatants of transfected COS-7 cells. As a control, a CCL21 full-length form was also produced in COS7 cells (referred to as St CCL21 wt). Both proteins displayed the expected molecular sizes as determined by western blotting on supernatants of transfected COS7 cells using a CCL21 specific antibody ( Figure 3B ). Recombinant CCL21, St CCL21 wt and St CCL21-stop were then compared in their chemotaxis-inducing ability on untreated and EndoNtreated mature DCs. As shown in Figure 3C , untreated DCs migrated better than EndoN-treated DCs to both recombinant CCL21 and St CCL21 wt. However, no differences in migration between untreated and EndoN-treated DCs towards St CCL21-stop were evidenced ( Figure 3C ). Thus, like for CCL19, St CCL21-stop-driven DC chemotaxis is not sensitive to PSA removal. Taken together, these observations indicate that the C-terminal region of CCL21 contributes to the in-creased migration observed in PSA-bearing DCs towards this chemokine and provides a suitable molecular explanation of why PSA does not affect migration of DCs towards CCL19.
Polysialylated NRP2 regulates CCL21-driven migration of DCs Polysialylation of NRP2 in DCs and its role in endothelial and tumor cell migration (Geretti et al. 2008; Pellet-Many et al. 2008 ) induced us to investigate its contribution to CCL21-and CCL19-driven DC migration by using siRNA technology to knock down its polysialylation (by ST8SiaIV siRNA) and expression (by NRP2 siRNA). Effective downregulation of ST8SIAIV expression in DCs after siRNA nucleofection was evidenced in all experiments performed by an almost complete abrogation of cellular PSA content ( Figure 4A , left panel) and by the shift of the smear corresponding to the NRP2 into a sharper and smaller size band, a feature consistent with the removal of the NRP2-attached PSA chains ( Figure 4A , right panel). Downregulation of ST8SiaIV expression resulted in a drastic drop of migration towards CCL21 but, in agreement with our former results, not towards CCL19 ( Figure 4B ). These results corroborate our previous conclusions by a different experimental approach and demonstrate that the enzyme ST8SiaIV mediates the incorporation of the PSA moieties implicated in CCL21-directed DC migration.
Since ST8SiaIV knockdown dramatically reduced the polysialylation extent of NRP2, we next investigated the influence of NRP2 expression on DC migration towards CCL21 and CCL19. Nucleofection of NRP2 siRNA in DCs resulted in reduction of NRP2 expression levels of 15%, 34% and 80% in three independent experiments with respect to those found in DCs nucleofected with GAPDH siRNA ( Figure 4A ) and led to a significant hampered migration of DCs towards CCL21 but not towards CCL19 ( Figure 4A and B) . The greater knockdown efficiency of ST8SiaIV siRNA with respect to NRP2 siRNA might explain why the effects in migration were more drastic in DCs nucleofected with the former siRNA. Since neither ST8SiaIV nor NRP2 siRNAs modified CCR7 expression levels ( Figure 4C) , the above results indicate that polysialylated NRP2 specifically controls CCL21-directed chemotaxis of DCs.
Discussion
This report provides evidence that PSA removal from mature DCs either by EndoN treatment or by knocking down the polysialyltransferase ST8SIAIV impairs their ability to migrate towards CCL21 but not towards CCL19. Our results, besides reinforcing the data reported by Bax et al. (2009) : (1) show that prevention of DC polysialylation impaired CCL21 activation of CCR7-migration-associated JNK and Akt signaling pathways, (2) highlight the critical role of the highly basic C-terminal region of the CCL21 chemokine for the PSA-enhancement effect on DC chemotaxis towards CCL21 and (3) demonstrate the contribution of the PSA acceptor molecule NRP2 to mature DC migration towards CCL21.
Since our experiments used LPS-induced mature DCs, a Toll-like receptor (TLR)-4-dependent maturation model, it should be investigated whether the enhanced PSA-mediated (C) CCR7 expression in untreated mature DCs and mature DCs nucleofected with GAPDH, NRP2 and ST8SiaIV siRNAs was determined by western blotting. Blots were stripped and probed for tubulin levels as a control for protein loading. The experiment shown is representative of three independent experiments. effect on DC migration towards CCL21 operates upon DC maturation triggered through activation of other TLR.
Interestingly, selective enhancement of CCL21-mediated chemotaxis might provide clues about the differential effects of CCL21/CCL19 on CCR7 recycling/degradation, desensitization and signaling (Kohout et al. 2004; Otero et al. 2006) .
Plasma membrane glycoprotein NRP2 has been identified as a PSA acceptor in mature DCs (Curreli et al. 2007) . Our experiments show that downregulating NRP2 expression (by NRP2 siRNA) or impairing its polysialylation (either by EndoN treatment or by ST8SiaIV siRNA) led to a significant reduction of DC migration towards CCL21. Altogether, these results point out that the PSA present on the structural context of NRP2 contributes to DC chemotaxis towards CCL21. Nevertheless, although western blotting analysis of lysates from mature DCs identified NRP2 as the most abundant polysialylated protein (Curreli et al. 2007 and our data), the contribution of other so far uncharacterized polysialylated acceptor proteins cannot be ruled out.
Besides mature DCs, NRP2 is preferentially expressed on lymphatic endothelial cells and some tumors, where it acts as a co-receptor for semaphorins 3B, C and F and some member of the VEGF family through their interactions with the signaltransducing receptors Plexins and VEGFR, respectively. Those interactions license NRP2 to contribute to neurogenesis, lymphangiogenesis and tumor progression via its key roles in axon guidance and endothelial and tumor migration and survival (Favier et al. 2006; Geretti et al. 2008; Pellet-Many et al. 2008 ). Our finding is consistent with the role of NRP2 in migration and adds novel perspectives of interest with regard to its post-translational modification by PSA and its functional cooperation with a chemokine receptor.
Finally, we have demonstrated that PSA-enhanced chemotaxis to CCL21 relies on its highly basic C-terminal region. This finding provides a structural framework that helps to explain why the PSA-enhancing effects on CCL21-directed DC chemotaxis were not seen for CCL19 ( Figure 5 ). The binding of CCL21 to PSA (Bax et al. 2009 ) and of its C-terminal basic region to glycosaminoglycans (Hirose et al. 2002) , in combination with our experimental data, make it reasonable to propose that the C-terminal basic region of CCL21 binds NRP2-coupled PSA. This interaction would presumably leave the N-terminal portion of the chemokine available (the region of chemokines known to be required for receptor binding (Allen et al. 2007 )), to interact with CCR7. According to this model, PSA-NRP2 would trap CCL21, increasing the local concentra- tion of the chemokine and/or enabling a proper CCL21-CCR7 docking. In any case, the formation of the ternary functional CCR7/PSA-NRP2/CCL21 complex could result in a lowering of the activation threshold of CCR7 and therefore in an increase of CCR7-mediated JNK and Akt signaling pathways. The higher effect on PSA-enhanced migration observed at lower doses of CCL21 supports the model proposed, which is reminiscent of the one proposed for the simultaneous binding of VEGF to neuropilins and VEGF receptors, and the enhancing effect of neuropilins on cell migration (Favier et al. 2006; Staton et al. 2007 ). In addition, binding of PSA-NRP2 to CCL21 might favor dimerization of the chemokine, protect it from proteolysis and/or enhance CCR7-independent signaling through NRP2-mediated signaling by itself or through its co-receptors, Plexins and/or VEGF receptors. Clearly, further investigation is required to unravel all of the above issues. The absence of a basic C-terminal region in CCL19 and in the St CCL21-stop mutant would preclude its interaction with PSA-NRP2 and therefore its integration in the CCR7/NRP2/ ST8SiaIV axis.
A direct association of CCR7 expression with lymph node metastasis in cancer patients has been found in a large variety of solid tumors (Zlotnik 2006) . On the other hand, NRP2 has been implicated in mediating proliferation, survival and migration of tumor cells (Bielenberg et al. 2006; Gray et al. 2008) , and PSA has been demonstrated to facilitate tumor invasion (Suzuki et al. 2005) . The functional cooperation reported here between CCR7, NRP2 and ST8SiaIV prompts further investigation of the relevance of this axis in tumors cell types that preferentially metastasize to secondary lymphoid organs.
Materials and methods
Reagents CCL21 and CCL19 chemokines were obtained from PreproTech. Antibodies against human CCL21, NRP2 and CCR7-phycoerythrin (for flow cytometry) were from R&D Systems. Anti-CCR7 for western blotting was obtained from AbCam. For PSA detection, the monoclonal antibody 735 was used (Frosch et al. 1985) . The anti-phospho-JNK(Thr183/Tyr185) and anti-phospho-Akt(Ser473) antibodies were purchased from Cell Signaling. Antibodies against actin and tubulin were from Sigma.
Generation of monocyte-derived dendritic cells
Monocyte-derived dendritic cells were generated from peripheral blood mononuclear cells of healthy donors as described (Puig-Kroger et al. 2006) . For maturation, immature DCs were treated with 100 ng/mL of LPS (Escherichia coli 0111:B4, InvivoGen) for 48 h. Acquisition of the DC mature phenotype was checked by flow cytometry using antibodies against CD83, CD86, CD209 and PSA.
EndoN treatment of DCs EndoN was purified as described (Hallenbeck et al. 1987) . Mature DCs at 2 × 10 6 cells/mL were incubated for 1 h at 37°C with either 5 U of EndoN at 1 U/mL (referred to as mDC-EndoN) or an equal volume of phosphate-buffered saline/glycerol in RPMI 1640, with occasional shaking. Afterwards, cells were washed with complete medium.
PSA removal after EndoN treatment was tested in all DCs preparations by western blotting and occasionally by flow cytometry using the monoclonal antibody 735.
Western blotting
Western blots were essentially performed as described (PuigKroger et al. 2006) . Briefly, 10 µg of each lysate were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and transferred onto an Immobilon polyvinylidene difluoride membrane (Millipore). ImageJ software was used for gel quantification analysis.
Site-directed mutagenesis of CCL21 and expression of CCL21 plasmids in COS7 cells Site-directed mutagenesis was performed on the pVAX-CCL21 construct (kindly provided by Dr. Y. Zhao, Medical Research Center, Shandong Provincial Hospital, Shandong University, Jinan (Li et al. 2006) ) using the QuikChange System (Stratagene). For the introduction of a stop codon in amino Cys 103 of human CCL21, the oligonucleotides GAAACCAGCC-CAGGGCTGAAGGAAGGACAGGGGGG, sense, and CCCCCCTGTCCTTCCTTCAGCCCTGGGCTGGTTTC, antisense, were used. This mutation gave rise to a CCL21 protein 31 amino acids shorter than the full-length form. The mutations of the resulting plasmid, designated as pVAX-CCL21-stop, were confirmed by DNA sequencing.
Vectors pcDNA3.1, pVAX-CCL21 and pVAX-CCL21-stop were transfected in COS7 cells by using Lipofectamine 2000 as recommended by the manufacturer. Supernatants were collected 48 h after transfection. Concentrations for each CCL21 form present in the supernatants were roughly estimated by western blotting by comparison with known amounts of recombinant CCL21.
Chemotaxis assays
Chemotaxis in response to chemokines CCL21 and CCL19 was determined by measuring the number of cells migrating through a polycarbonate filter (5-µm pore size) in 24-well transwell chambers (Costar Europe). The upper chamber included 1 × 10 5 DCs diluted in 100 µL of RPMI 1640 medium and 0.1% bovine serum albumin, and the lower chamber contained 600 µL of the same medium with or without chemokines (at 200 ng/mL, unless otherwise indicated). DCs that migrated to the bottom chamber (after 2 h at 37°C) and inputs were counted by flow cytometry using CellQuest software (BD Biosciences). Percentage of migration was expressed relative to the number of input cells after subtracting the number of cells migrated in the absence of chemokines from the values obtained in the presence of chemokine in the lower chamber. COS7 cell supernatants containing CCL21-wt and CCL21-stop forms were used at doses estimated to be within a range between 100 and 200 ng/mL.
Nucleofection in DCs of siRNAs
Immature DCs (2-4 × 10 6 ) were transfected with 600 nmol of each siRNA (Ambion) using the Amaxa human dendritic cell nucleofector kit following the manufacturer's instructions. Sense siRNAs used were: GAPDH: (ref 4390850, Ambion); ST8SiaAIV:CCUCCUACCUGAAGUUUCAtt; NRP2: AGAUUGUCCUCAACUUCAAtt. One hour later, DCs were matured by the addition of 100 ng/mL of LPS. Experiments were carried out 36 h later. Downregulation of protein expression levels for NRP2 was assayed by western blotting using an anti-NRP2 antibody. ST8SiaIV downregulation was indirectly determined by detection of PSA levels by western blotting using the 735 antibody.
Signaling assays
Signaling experiments were basically as described (Riol-Blanco et al. 2005) . DCs were stimulated with CCL21 at 200 ng/mL for the indicated times. JNK and Akt activation was assayed with anti-phospho-JNK(Thr183/Tyr185) and anti-phospho-Akt (Ser473) antibodies, respectively.
Statistical analysis
Statistical analyses were performed using the paired Student's t-test. A value of P equal to or less than 0.05 was considered significant.
